TY - JOUR
AU - Krigel, Robert L.
AB - THE JOURNAL OF INFECTIOUS DISEASES. YOL. 154, NO. I • JULY 1986 © 1986 by The University of Chicago. All rights reserved. 0022-1899/86/5401-0028$01.00 CORRESPONDENCE Attempts to restart treatment with the drug led to recurrent Reversible Neurotoxicity Due to Oral Acyclovir symptoms. In February 1985, after four months without acyclovir in a Patient with Chronic Lymphocytic Leukemia and after several attacks of herpes-like lesions, the patient restarted treatment with acyclovir; he initially received 200 mg every other COLLEAGUES-Oral acyclovir has recently been approved "for the day and later received 200 mg daily. At this dosage, he has had treatment of initial episodes and the management of recurrent only four brief recurrences of herpes-like lesions and has not had episodes of genital herpes in certain patients" [1]. It is relatively any associated fatigue or lethargy. safe, well tolerated, and without significant side effects. A vari­ Oral acyclovir is now an accepted treatment for first episodes ety of neurological symptoms have been associated with the use of genital infection with herpes simplex virus. Recent reports [6-8] of parenteral acyclovir [2-5]. None, however, has been reported have demonstrated that prophylactic oral acyclovir helps prevent with the use of oral acyclovir. recurrent infections with 
TI - Reversible Neurotoxicity Due to Oral Acyclovir in a Patient with Chronic Lymphocytic Leukemia
JO - The Journal of Infectious Diseases
DO - 10.1093/infdis/154.1.189
DA - 1986-07-01
UR - https://www.deepdyve.com/lp/oxford-university-press/reversible-neurotoxicity-due-to-oral-acyclovir-in-a-patient-with-Dbb6AG74PH
SP - 189
EP - 189
VL - 154
IS - 1
DP - DeepDyve
ER -